uniQure (NASDAQ:QURE) Insider Walid Abi-Saab Sells 45,000 Shares

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 45,000 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the transaction, the insider directly owned 169,669 shares in the company, valued at $4,251,905.14. The trade was a 20.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Walid Abi-Saab also recently made the following trade(s):

• On Wednesday, March 4th, Walid Abi-Saab sold 808 shares of uniQure stock. The stock was sold at an average price of $9.06, for a total transaction of $7,320.48.

uniQure Stock Up 5.3%

Shares of QURE stock traded up $1.46 during trading hours on Tuesday, hitting $29.10. 4,065,796 shares of the company were exchanged, compared to its average volume of 2,891,632. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The business’s 50-day simple moving average is $16.94 and its two-hundred day simple moving average is $24.23. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -8.36 and a beta of 0.87.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.21 million. Sell-side analysts predict that uniQure N.V. will post -3.68 EPS for the current fiscal year.

Hedge Funds Weigh In On uniQure

A number of large investors have recently bought and sold shares of QURE. Torren Management LLC bought a new position in uniQure in the fourth quarter worth about $28,000. Jones Financial Companies Lllp lifted its holdings in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 509 shares during the last quarter. IFP Advisors Inc bought a new position in uniQure in the fourth quarter worth about $48,000. Smartleaf Asset Management LLC bought a new position in uniQure in the fourth quarter worth about $48,000. Finally, CIBC Private Wealth Group LLC bought a new position in uniQure in the third quarter worth about $50,000. Institutional investors own 78.83% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $15.00 to $60.00 in a research report on Monday, March 9th. The Goldman Sachs Group increased their price target on shares of uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a research report on Monday, April 20th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $9.00 price target (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Barclays cut their target price on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Finally, Chardan Capital raised their target price on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $42.83.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.